Industry and others warn on upholding competitive clinical trial authorization timelines

27 November 2013

Improving the attractiveness and competitiveness of Europe as a prime location for clinical research - which is conducted globally - was a key driver for the revision of the European Union clinical trial legislation, which aimed to reduce unnecessary red tape whilst preserving, the quality and safety of clinical trials.

The European legislators are expected to reach a compromise on the Clinical Trials Regulation before Christmas. The industry trade groups European Federation of Pharmaceutical Industries and Associations (EFPIA) and EuropaBio, as well as others, call on all parties to bear the drivers of this legislative revision in mind and take the steps needed to grow EU clinical research. It is imperative to build on Europe’s innovative edge – not just for competitive reasons, but because innovation is the tool needed to deliver new and improved medicines to patients.

The longer the trial process the greater the cost

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >